Topotecan weekly bolus chemotherapy for relapsed platinum-sensitive ovarian and peritoneal cancers

OBJECTIVE: Topotecan at a dose of 1.5 mg/m(2) on days 1 to 5 of a 21-day cycle is an approved therapy for recurrent ovarian cancer. However, heavily pretreated patients may be predisposed to hematologic adverse events. This prospective study, therefore, investigates the safety and efficacy of an alt...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Morris, Robert, Alvarez, Ronald D., Andrews, Stephen, Malone, John, Bryant, Christopher, Heilbrun, Lance K., Smith, Daryn, Schimp, Veronica, Munkarah, Adnan
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2008
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3865862/
https://ncbi.nlm.nih.gov/pubmed/18410954
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2008.02.028
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia